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Enoyl acyl carrier protein reductase (ENR) is involved
in fatty acid biosynthesis. In Escherichia coli this en-
zyme is the target for the experimental family of anti-
bacterial agents, the diazaborines, and for triclosan, a
broad spectrum antimicrobial agent. Biochemical stud-
ies have suggested that the mechanism of diazaborine
inhibition is dependent on NAD1 and not NADH, and
resistance of Brassica napus ENR to diazaborines is
thought to be due to the replacement of a glycine in the
active site of the E. coli enzyme by an alanine at position
138 in the plant homologue. We present here an x-ray
analysis of crystals of B. napus ENR A138G grown in the
presence of either NAD1 or NADH and the structures of
the corresponding ternary complexes with thienodiaza-
borine obtained either by soaking the drug into the crys-
tals or by co-crystallization of the mutant with NAD1
and diazaborine. Analysis of the ENR A138G complex
with diazaborine and NAD1 shows that the site of diaza-
borine binding is remarkably close to that reported for
E. coli ENR. However, the structure of the ternary ENR
A138G-NAD1-diazaborine complex obtained using co-
crystallization reveals a previously unobserved confor-
mational change affecting 11 residues that flank the
active site and move closer to the nicotinamide moiety
making extensive van der Waals contacts with diazabo-
rine. Considerations of the mode of substrate binding
suggest that this conformational change may reflect a
structure of ENR that is important in catalysis.
Enoyl acyl carrier protein reductase (ENR)1 is a key compo-
nent of type II fatty acid synthetase, which is found in both
plants and bacteria (1). It catalyzes the second reductive step in
the fatty acid biosynthesis pathway, converting a trans-2,3
enoyl moiety into a saturated acyl chain, and utilizes NAD(P)H
as a cofactor. The study of this enzyme as a drug target has
recently received increased attention in connection with the
discovery that three distinctly different synthetic anti-bacterial
drugs, isoniazid (2), diazaborine (3, 4), and triclosan (5, 6) block
lipid biosynthesis in bacteria by inhibiting ENR. The recent
structural studies on diazaborine-bound Escherichia coli ENR
(7) elucidated the mechanism by which diazaborine inhibits
bacterial ENR and also threw light onto the molecular nature
of the E. coli ENR G93S mutant’s resistance to diazaborines
(8). These studies indicate that a Gly933 Ser substitution puts
the larger amino acid side chain at the position where it would
clash with the sulfonyl oxygens of the diazaborine molecule.
The Brassica napus and the E. coli enoyl reductases share 35%
sequence identity, and structural comparison of the two en-
zymes has shown that the amino acid residues forming the
active site are highly conserved between the two proteins (7, 9).
However, in contrast to the E. coli enzyme, B. napus ENR is
insensitive to diazaborine (4). Molecular genetic and biochem-
ical studies on mutants of B. napus ENR (10) have suggested
that the presence of an alanine residue at position 138 of B.
napus ENR (structurally equivalent to position 93 in the E. coli
enzyme) is the major determinant for its resistance to diaza-
borine. Furthermore, kinetic studies on E. coli ENR and B.
napus ENR A138G (4, 10) have shown that, although diazabo-
rine inhibits ENR in the presence of NAD1, the compound’s
inhibitory activity with NADH is hardly detectable.
In order to analyze the molecular basis of resistance and
sensitivity to diazaborine of B. napus ENR and to assess the
role of the oxidized and reduced forms of the cofactor in the
formation of the enzyme-nucleotide-diazaborine complexes, we
have determined and analyzed the x-ray crystal structures of
the A138G mutant of B. napus ENR complexed with either
NAD1 or NADH both in the presence and absence of thienodi-
azaborine. In this paper we report the results of this analysis
and also compare the effect of producing these complexes by
soaking versus co-crystallization, which reveals a conforma-
tional change on drug binding that we presume to be linked to
substrate recognition.
EXPERIMENTAL PROCEDURES
Preparation of Crystal Complexes
The diazaborine-sensitive B. napus ENR A138G mutant has an
enzymatic activity closely related to that of the wild type enzyme and
was prepared as described previously (10). Co-crystallization of ENR
A138G with either oxidized or reduced form of the cofactor was con-
ducted using 4-ml drops containing 15 mg/ml (0.45 mM) ENR A138G, 1.5
mM NAD1 or NADH in either 0.05 M MES, pH 6.0, for NAD1 or 0.05 M
HEPES, pH 8.0, for NADH, mixed with the same volume of the reser-
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voir solution containing 1.8 M (NH4)2SO4 and 0.1 M of the appropriate
buffer, and equilibrated against the reservoir solution at 17 °C. The
crystals are isomorphous to those of the wild type enzyme and belong to
the space group P42212 with cell dimensions a 5 b 5 70.5 Å, c 5 117.5
Å for the NAD1 complex (c 5 117.7 Å for the NADH complex), and with
a monomer in the asymmetric unit. Ternary complexes of ENR A138G
(containing the cofactor and thienodiazaborine) were obtained both by
soaking and co-crystallization experiments. The soaking of the inhibitor
into the “binary” crystals was conducted for 4 h using a stabilizing
solution containing 5 mM thienodiazaborine and 3 mM NAD1 or NADH.
Co-crystallization experiments were conducted in hanging drops, con-
taining 7.5 mg/ml ENR A138G, 1.5 mM NAD1, 0.75 mM thienodiazabo-
rine, 2.25 M NaCl and 50 mM sodium acetate, pH 5.3, suspended over a
well solution containing 4.5 M NaCl and 50 mM sodium acetate, pH 5.3.
The latter crystals represent a new crystal form (hereafter referred to
as form B) and belong to the space group I4122 with cell dimensions a 5
b 5 104.6 Å, c 5 284.0 Å and with a dimer in the asymmetric unit.
X-ray Data Collection
X-ray diffraction data for both the binary complexes as well as for the
diazaborine-soaked crystals were collected at room temperature on a
twin San Diego multiwire systems (SDMS) area detector with Rigaku
RU-200 rotating anode source. The data were processed and merged
using SDMS software (11). X-ray diffraction data for the form B crystal
complex were collected from a crystal cooled to 100 K using an Oxford
Cryosystems Cryostream device to 2.5 Å on a MAR image plate detector
on station 9.6 at the Synchrotron Radiation Source Daresbury Labora-
tory. A cryoprotectant solution contained 20% glycerol, 3.7 M NaCl, 3
mM NAD1, 1.5 mM thienodiazaborine, and 50 mM sodium acetate, pH
5.3. The data were processed using the DENZO/SCALEPACK package
(12). A summary of the data-processing statistics is presented in Table
I. Subsequent data handling employed the CCP4 program suite (13).
Structure Determination and Refinement
Binary ENR A138G-NAD(H) Complexes—The same procedure was
applied in building the models for both of the binary complexes. The
starting coordinates were those of the wild type B. napus ENR complex
with NAD1 (Protein Data Bank (PDB) code 1eno) or NADH (PDB code
1enp) (14) with Ala138 replaced by Gly, and the cofactor and all waters
excluded. These models were used to calculate initial electron density
(2Fobs 2 Fcalc) and (Fobs 2 Fcalc) maps, which showed readily interpret-
able electron density either for the reduced or for the oxidized form of
the cofactor. In case of the NAD1-complex, the electron density in the
region of the nicotinamide ring, its associated ribose, and the pyrophos-
phate moiety was very weak. The cofactors were incorporated into the
respective models, which were then submitted to rounds of restrained
positional and isotropic B-factor refinement using the TNT program
(15), including a correction for the solvent continuum (16). The struc-
tures were rebuilt where necessary using the FRODO program (17).
Water molecules were introduced during the course of the refinement at
geometrically reasonable positions, but those with the refined value of
the B-factor above 70 Å2 were deleted from the coordinate list. Analysis
of the stereochemical quality of the models was accomplished using the
PROCHECK program (18). Refinement statistics are summarized in
Table I.
Ternary ENR A138G-NAD(H)-Diazaborine Complexes Obtained by
Soaking—For each of the ternary complexes obtained by soaking, the
starting coordinates were those of the respective binary complex with
the cofactor and all waters excluded. These models were used to calcu-
late initial electron density (2Fobs 2 Fcalc) and (Fobs 2 Fcalc) maps, which
in both cases clearly showed the position of the diazaborine and a cofactor
in the active site of ENR A138G. Both cofactor and inhibitor molecules
were incorporated into the models, which were then submitted to the
refinement procedure that was essentially the same as described for the
binary complexes. Refinement statistics are presented in Table I.
ENR A138G-NAD1-Diazaborine Complex Obtained by Co-crystalli-
zation—Since the crystallization of ENR A138G in the presence of
NAD1 and thienodiazaborine led to the appearance of a previously
unobserved crystal form (form B), the structure was solved by molecular
replacement using a search model based on a dimer of the ternary ENR
A138G-NAD1-diazaborine complex, produced by soaking the drug into
crystals, with the cofactor, diazaborine, and all waters excluded. Mo-
lecular replacement was performed using the AMORE program (19).
The rotation function yielded one hit that was clearly above the others
(a 5 39°, b 5 90°, g 5 281°). This top hit was then used in a translation
search. The top hit from the translation function (TF 5 19.7 s, frac-
tional translation parameters tx 5 0.122, ty 5 0.596, tz 5 0.048) was
then rigid-body refined from a starting R-value of 0.41 to 0.35 using
data in the range 10–3.5 Å. The resultant electron density maps with
coefficients (2Fo 2 Fc) and (Fo 2 Fc) at 2.5 Å showed clear density for the
NAD1 molecules bound in the active site of each monomer as well as
density for the inhibitor. Inspection of electron density maps in the
region of the enzyme active site also revealed a substantial conforma-
tional change for the part of the chain comprising residues 236–246 in
both of the subunits. These residues were moved to the correct positions
indicated by an omit map, and the NAD1 and diazaborine molecules
were also incorporated into the model. Following restrained positional
refinement of the atomic coordinates with all B-factors fixed at 25 Å2,
the R-factor of the model dropped to 0.299 for data in the range 10–2.5
Å. From then on, the structure was refined by successive cycles consist-
ing of restrained positional and isotropic B-factor refinement, including
a correction for solvent continuum followed by manual rebuilding using
the FRODO program. Water molecules were introduced during the
course of the refinement at geometrically reasonable positions, but
these only retained upon refinement if their B-factors remained below
60 Å2. Refinement statistics are summarized in Table I.
FIG. 1. a, chemical structure of thienodiazaborine used in the present study. b, the Fourier map of the refined model for the ENR A138G-NAD1-
thienodiazaborine complex, obtained by soaking the drug into the crystals of the NAD1-bound ENR A138G, at 2.1-Å resolution with the final
refined structure superimposed. The density was calculated with coefficients (2Fo 2 Fc) and contoured at 1 s. There was no interpretable electron
density for the terminal methyl group of the propyl moiety of the thienodiazaborine. The boron atom of diazaborine is colored green (the covalent
linkage between this atom and the 29 hydroxyl of the nicotinamide ribose is not shown). The mutated residue (A138G) is labeled, and the position
of the Cb of the Ala
138 side chain, as observed in the wild type diazaborine-insensitive enzyme, is shown with a dashed line (produced using O;
Ref. 22).
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RESULTS AND DISCUSSION
Analysis of the Structures of the Binary Complexes—The
ENR A138G mutant crystallizes in the presence of both the
oxidized and reduced forms of the cofactor isomorphously to the
corresponding binary wild type enzyme complexes (14). There-
fore, the structures of both the binary complexes were solved
directly by refinement starting from the corresponding coordi-
nates of the binary complexes of the wild type enzyme (see
“Experimental Procedures”). For both the complexes, the over-
all protein structure was found to be essentially identical to
that of the wild type enzyme and no structural rearrangements
were observed in the vicinity of the mutation. Like in the
structure of the wild type ENR-NAD1 complex, the electron
density for the NAD1 in the mutant enzyme was good for the
adenine ring and its associated ribose sugar, very poor for the
pyrophosphate moiety, and there was no interpretable density
for the nicotinamide moiety and its associated ribose sugar,
consistent with the temperature factor for these parts of the
cofactor molecule reaching the upper cut-off limit of 100 Å2
during refinement. In the ENR A138G-NADH complex, the
density for the entire NADH molecule was readily interpreta-
ble, although that for the pyrophosphate moiety was somewhat
less well defined. The location and the extended conformation
for the NADH molecule with both ribose sugars being in C29-
endo conformation was found to be very similar to that de-
scribed for the corresponding wild type ENR binary complex
(14). Comparison of the structures of ENR A138G with NAD1
and NADH bound shows that the only major difference in the
conformation of the protein occurs in the position of the side
chain of Tyr32. In the NAD1-bound structure, this residue
adopts a well defined conformation and occupies part of the
binding pocket for the nicotinamide moiety. In the NADH-
bound ENR A138G structure, the side chain of Tyr32 moves so
that the volume of the binding pocket increases compared with
the complex with NAD1, allowing the reduced nicotinamide
ring to occupy the binding site where it is stabilized by van der
Waals contact with the edge of the phenolic ring of the tyrosine.
This situation is equivalent to the structural change that oc-
curs on NADH versus NAD1 binding with the wild type
enzyme.
Location of the Diazaborine Binding Site in the Crystals of
ENR A138G Grown in the Presence of NAD1 or NADH—Pre-
vious enzyme inhibition assays on E. coli ENR and B. napus
ENR A138G (4, 10), which followed the oxidation of NADH in
the presence or absence of diazaborine, have been carried out
using crotonyl-CoA as a substrate. These kinetic studies
showed that, whereas the initial velocity of the reaction was
hardly affected by diazaborine, the inhibitory effect increased
during the course of the reaction, pointing to the involvement of
a reaction product, NAD1, rather than NADH, in the mecha-
nism of diazaborine inhibition.
However, our experiments on soaking thienodiazaborine
(Fig. 1a) into the “binary” crystals of ENR A138G with NAD1
or NADH produced electron density maps for both complexes,
which are qualitatively very similar and show clear electron
density for the entire cofactor and the drug in both structures.
Thus, binding of diazaborine to the ENR A138G-NAD1 com-
plex has resulted in the ordering on the enzyme surface of those
parts of the NAD1 molecule that are disordered in the binary
complex. In addition, the movement of Tyr32 associated with
localizing the nicotinamide ring, which had previously only
been observed in the structure of the binary complex with
NADH, was also seen. Analysis of the structure of the complex
obtained through soaking crystals of the binary complex with
NADH in diazaborine shows no features different from the
complex with NAD1 and diazaborine.
In both structures, thienodiazaborine stacks onto the nico-
tinamide ring of the cofactor (Fig. 1b) and makes further van
der Waals contacts with the side chains of Tyr188, Met202,
Lys206, Ile244, and Ile247 and with the main-chain peptide be-
tween Gly138 and Gly140. The boron hydroxyl forms a hydrogen
bond with the phenolic hydroxyl of Tyr198. Of considerable
importance in stabilizing the diazaborine in the active site are
extensive p-p stacking interactions formed between the bicyclic
rings of the diazaborine and the nicotinamide ring. The stack-
ing involves only partial overlap of the rings so that the car-
bamide group of the nicotinamide moiety forms close contact
with the adjacent ring system. This stacking interaction is
closely related to that observed in the E. coli ENR-NAD1-
diazaborine complex (7).
In the structures of the B. napus ENR A138G complexes with
either the oxidized or reduced form of the cofactor and thieno-
diazaborine, the boron atom of the drug and the 29 hydroxyl of
the nicotinamide ribose are clearly covalently linked, and the
TABLE I
Crystallographic data
ENR A138G crystal complex NAD1 NADH
NAD1,
diazaborine
(soaking)
NADH,
diazaborine
(soaking)
NAD1, diazaborine (form B)
X-ray data collection statistics
Resolution limit (Å) 2.1 2.0 2.1 2.4 2.5
No. of observed reflections 69,587 76,971 52,166 47,298 90,629
No. of unique reflections 18,081 18,245 16,038 10,933 25,755
Completeness (outer shell) (%) 94 (74) 88 (88) 85 (63) 87 (67) 93 (93)
Rmerge
a (outer shell) 0.051 (0.165) 0.076 (0.217) 0.051 (0.180) 0.086 (0.220) 0.057 (0.188)
Refinement statistics
Resolution (Å) 10–2.1 10–2.0 10–2.1 10–2.4 10–2.5
No. of reflections used 17,154 17,346 15,218 10,354 24,431
Rcryst
b 0.160 0.158 0.164 0.174 0.211
Rfree
c 0.209 0.207 0.229 0.242 0.314
No. of solvent molecules 103 108 94 76 113
Bond-length rms deviation (Å) 0.013 0.010 0.011 0.011 0.012
Bond-angle rms deviation (°) 1.7 1.5 1.5 1.7 1.4
Ramachandran plot (%)d 92 (8) 92 (8) 93 (7) 92 (8) 90 (10)
Average B (protein) (Å2) 22 29 21 24 32
Average B (cofactor) (Å2) 75 42 37 46 30
Average B (diazaborine) (Å2) 37 51 24
a Rmerge 5 (hkluIj 2 Imu/(hklIm, where Ij and Im are the observed intensity and mean intensity of related reflections, respectively.
b Rcryst 5 (hkl(uFobsu 2 uFcalcu)/(hkluFobsu.
c Rfree was calculated on 5% of the data omitted at random.
d The percentage of non-glycine and non-proline residues falling within the most favored and allowed regions (in parentheses).
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arrangement of the four atoms closest to the boron is tetrahe-
dral in both the ternary complexes. This is similar to the
situation with the E. coli enzyme and indicates that on diaza-
borine binding, the boron atom undergoes conversion from sp2
hybridization state to sp3 and forms a covalent bond with the 29
oxygen of the nicotinamide ribose of either NAD1 or NADH.
Superposition of the two ternary complexes based on the over-
lap of 296 Ca with a root mean square deviation of 0.2 Å shows
that, within the limit of the experimental error in the coordi-
nates (0.23 and 0.29 Å for the ENR A138G-NAD1-diazaborine
and the ENR A138G-NADH-diazaborine complexes, respec-
tively, as determined by SIGMAA; Ref. 20), their structures are
essentially identical.
Taking into account the results of kinetic studies (4, 10),
which indicate that diazaborine acts as an inhibitor of the enoyl
reductase in the presence of NAD1 and not NADH, the ener-
getics of the formation of these two distinct complexes would be
expected to be significantly different. Therefore, at first sight
the structural similarity of the B. napus ENR A138G-NAD1-
diazaborine and the ENR A138G-NADH-diazaborine com-
plexes is surprising. There are currently two possible explana-
tions for this. First, the structures of the ternary complexes
might be very similar, but the difference in the oxidation state
of the nicotinamide ring for NAD1 and NADH would result in
a distinct difference in the strength of the interactions with the
enzyme and diazaborine. Thus, for NAD1, the charge on the
nicotinamide ring, the presence of aromaticity, and the loss of
the hydride could influence the affinity of the site for diazabo-
rine. In particular, a possible stabilizing feature could be the
full negative charge on the boron of the diazaborine interacting
with the oxidized nicotinamide ring. If this is the case, then the
difference in affinity is not reflected in any dramatic changes in
the structure. Indeed, the only difference of the complex with
NADH compared with that with NAD1 appears to be an ap-
parent increase of 9 and 14 Å2 in the average temperature
factors of the nucleotide and diazaborine molecules, respec-
tively, in the NADH complex (Table I). However, at this stage,
we attach little significance to this difference since it is small
and the lower resolution of the analysis of the complex with
NADH and diazaborine precludes accurate refinement of the
FIG. 2. a, ribbon representation of the ENR A138G-NADH binary complex in the region of the active site. Residues 236–246 are shown in
magenta. b, ribbon representation of the ENR A138G-NAD1-thienodiazaborine ternary complex, obtained by co-crystallization, in the same view
as in a. The diazaborine molecule is drawn in green. Residues 236–246 are shown in magenta, and the shift in position of this loop compared with
that seen in the binary complex with NADH is evident. c, ribbon diagram of the E. coli ENR-NAD1-thienodiazaborine complex (PDB code 1dfh)
superimposed on the B. napus ENR A138G-NAD1-thienodiazaborine complex, obtained by co-crystallization. The diagram illustrates the
remarkably similar mode of diazaborine binding. The backbone atoms are shown in blue for B. napus ENR A138G and orange for E. coli ENR. The
NAD1 and the diazaborine molecules bound to B. napus ENR A138G are colored green; those bound to E. coli ENR are magenta. The equivalent
loops 192–202 (E. coli ENR) and 236–246 (B. napus ENR A138G) are labeled, and their difference in position is clear. d, stereoview of the
diazaborine-binding sites of the superimposed B. napus ENR A138G-NAD1-thienodiazaborine complex, obtained by co-crystallization, and E. coli
ENR-NAD1-thienodiazaborine complex. The diazaborine and the nicotinamide moiety and its associated ribose are shown only for the B. napus
ENR ternary complex, in ball-and-stick representation with carbon atoms colored gray, nitrogen blue, sulfur yellow, oxygen red, and boron orange.
For clarity, only the key residues responsible for diazaborine binding are shown, and the rest of the chains are drawn schematically in thin lines.
B. napus ENR is drawn in magenta and E. coli ENR in green. Residues are labeled in B. napus ENR. e, ribbon diagram of the model of the enoyl
substrate fitted into the B. napus ENR A138G active site. The cofactor molecule, the enoyl, and pantetheine moieties of the enoyl ACP are shown
in all-atom representation with the carbon atoms colored orange (cofactor) and black (substrate). The proposed locations of the growing acyl chain
(R) and the ACP molecule are marked. Residues 236–246 are shown in magenta. The pantetheine moiety of the substrate was modeled using the
structure of that in the CoA molecule, as observed in the crystal structure of the citrate synthase complex with CoA and citrate (PDB code 2cts)
(26), with the torsion angles adjusted such that there was no steric clash with atoms of the protein. f, stereoview of superposition of bound
diazaborine and a model for the enoyl substrate. The carbon atoms are colored orange in the cofactor and diazaborine molecules and black in the
substrate model (O, red; N, blue; S, yellow; P, magenta; B, green). The proposed locations of the growing acyl chain (R) and the ACP molecule are
marked. (The figures were prepared using MIDAS (23).)
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temperature factors. The second possibility is more compli-
cated and arises from the presence in most samples of NADH of
contaminating quantities of NAD1. In the binary complexes of
B. napus ENR A138G, the identity of the respective oxidized or
reduced cofactor in the structures can be inferred from the
clear difference in the electron density maps and the ordering
of the nicotinamide ring in the complex with NADH. However,
for the structures of the two ternary complexes, we cannot
preclude the possibility that during the soaking of the crystals
of the binary ENR A138G-NADH complex in a solution con-
taining diazaborine and NADH, the NADH initially present in
the crystal has been exchanged for contaminating NAD1,
which, while binding to the enzyme with lower affinity than
NADH, could be stabilized by the binding of diazaborine. At the
FIG. 2—continued
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resolution of this study, we cannot expect to distinguish the
difference in the structure of the cofactor due to the different
nature of the oxidized and reduced states of the nicotinamide
ring. Therefore, our current interpretation of the data is com-
plicated by a potential uncertainty concerning the nature of the
bound cofactor in the complex with NADH and thienodiazabo-
rine. Further work is needed to clarify this.
Co-crystallization of ENR A138G with NAD1 and Diazabo-
rine Reveals a Substantial Conformational Change in the Pro-
tein Active Site—The search for conditions for co-crystallization
of the enzyme with both the cofactor and the inhibitor yielded
crystals for the ternary ENR A138G-NAD1-thienodiazaborine
complex, that grew from a buffered solution of NaCl. These
crystals were found to belong to a different space group (I4122).
The structure of the complex was determined by the molecular
replacement procedure and revealed that the part of the chain
comprising the residues 236–246 is significantly shifted from
the position observed in the binary complexes with NAD1 or
NADH. In the new crystal form, this loop adopts a regular
helical conformation, which forms an additional edge of the
diazaborine-binding site and makes it less accessible to the
solvent (Fig. 2, a and b). This motion draws the residues Ala240
and Ala241 closer to the diazaborine so that now both their
side-chain and main-chain atoms make extensive van der
Waals contacts with the edge of the fused rings of the inhibitor.
In addition, the hydroxyl of Ser238 now approaches within
hydrogen bonding distance of one of the oxygens of the pyro-
phosphate moiety. Given that diazaborine is thought to mimic
the enzyme’s natural enoyl substrate (7), these findings provide
a potential explanation for the strong conservation of the ala-
nine residue at position 240 of B. napus ENR in the aligned
sequences of representative enoyl reductases (Fig. 3). Further-
more, at position 238, the ENR sequences show a preference for
either serine or threonine, both of which contain a hydroxyl
that could interact similarly with the pyrophosphate moiety of
the nucleotide cofactor. Overall, this suggests that these two
residues are essential for ENR activity and the conformational
change of the 236–246 loop seen in the crystal structure of the
B. napus ENR A138G-NAD1-thienodiazaborine represents a
key step in the enzyme’s catalytic cycle. This important struc-
tural adjustment, which favors the tight binding of both the
cofactor and the inhibitor, was not observed when the ternary
complex was produced by soaking diazaborine into the crystals
of the binary complex of the mutant enzyme with either re-
duced or oxidized form of the cofactor. One possible explanation
for this is that in the crystal form observed for the binary
complexes of B. napus ENR A138G with NADH or NAD1 the
loop 236–246 is involved in crystal packing interactions in
which the main-chain carbonyl oxygen of Ala241 and peptide
nitrogens of Ala241 and Lys242 make hydrogen bonds with the
side-chain amide group of Gln70 in a symmetry-related
molecule.
Superposition of the structures of B. napus ENR A138G
co-crystallized with NAD1 and thienodiazaborine and the cor-
responding wild type E. coli ENR co-crystallized complex (PDB
code 1dfh) (7) reveals that 204 Ca atoms can be overlapped with
a root mean square deviation of 0.9 Å (Fig. 2, c and d), indicat-
ing the overall similarity of the two enzymes, despite there
being only 35% sequence identity between them (9). Inspection
of the superimposed structures further revealed that the mode
of diazaborine binding is remarkably similar, with a large
number of conserved residues involved in interaction with di-
azaborine in B. napus ENR A138G and in E. coli ENR (in
parentheses) as follows: Gly138 (Gly93), Tyr188 (Tyr146), Tyr198
(Tyr156), Met202 (Met159), Lys206 (Lys163), Ile244 (Ile200), and one
conservative amino acid substitution (Ile247 (Phe203)) (Fig. 2d).
The most noticeable difference between the two structures
concerns the position of the 236–246 loop in B. napus ENR
A138G and the corresponding loop 192–202 in the E. coli wild
type enzyme. In the structure of the E. coli ENR complex with
NAD1, this loop is completely disordered (21), whereas in the
co-crystal of the E. coli ENR with NAD1 and thienodiazaborine
it is observed in a well defined position in one of the two
subunits in the asymmetric unit. A comparison of the latter
structure with that of the co-crystal of B. napus ENR A138G
with NAD1 and diazaborine shows that the 236–246 loop in
the B. napus enzyme and the 192–202 loop in the E. coli
enzyme adopt different conformations (Fig. 2c). In contrast to
the situation in the B. napus ENR A138G complex with NAD1
and diazaborine, where strongly conserved residues Ser238 and
Ala240 make contacts with the NAD1 and inhibitor molecules,
the equivalent residues in the structure of the E. coli complex
(Thr194 and Ala196) make no such contacts. However, recent
further refinement of the structures of the diazaborine com-
plexes of E. coli ENR2 has revealed that the two subunits in the
2 C. W. Levy and J. B. Rafferty, personal communications.
FIG. 3. Sequence comparison of the
region surrounding the residues
Ser238, Ala240, and Ala241 in B. napus
ENR with other known and putative
enoyl reductases. Highlighted are the
functionally conserved residues at posi-
tions equivalent to Ser238 and Ala240 in B.
napus ENR.
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asymmetric unit of these crystals adopt different conformations
for the 192–202 loop, one of which is closely related to the
helical loop structure seen in the B. napus ENR A138G.
Together, these data suggest that the flexibility of this part
of the structure is essential for the enzyme’s function. Further-
more, close contacts of the inhibitor and the strongly conserved
residues Ser238 and Ala240 seen in the structure of B. napus
ENR A138G co-crystallized with NAD1 and thienodiazaborine
suggest that the helical loop conformation is more likely to
represent a catalytically important conformation than that pre-
viously reported for the E. coli enzyme.
A proposed catalytic mechanism for enoyl ACP reduction by
B. napus ENR involves hydride transfer from the C4 position of
NADH to the C3 carbon atom of the enoyl moiety of the sub-
strate followed by donation of a proton to the oxygen of the
resultant enolate anion from the side chain of Tyr198 (14).
Lys206 is thought to be a second catalytic residue, whose amino
group might stabilize the negatively charged transition state.
Analysis of arrangement of the key residues around the nico-
tinamide moiety of the cofactor in the ENR active site and the
mode of diazaborine binding to ENR allows us to propose a
model for the binding of the natural enoyl substrate. In this
model (Fig. 2, e and f), the acyl chain of enoyl ACP is placed
above the nicotinamide ring of the cofactor in such a way that
the double bond reduced by ENR during catalysis (between the
C2 and C3 positions in the enoyl moiety of the substrate) lies
over and parallel to the C4-C5 double bond in the nicotinamide
ring, with the carbonyl group and the C2, C3, and C4 atoms of
the enoyl moiety lying in the plane of the aromatic bicyclic ring
of diazaborine. The angle formed between the C3 atom of the
enoyl moiety of the substrate and the C4 and N1 atoms of the
nicotinamide ring is close to 100°. With this arrangement of the
modeled enoyl moiety of the substrate and the nicotinamide
ring of the cofactor, the geometry requirements for hydride
attack on the natural enoyl substrate are fulfilled (24, 25). The
proposed position of the carbonyl oxygen atom of the enoyl
moiety is close to that of the boron atom in diazaborine and
implies formation of the hydrogen bonds with both the 29-
hydroxyl of the nicotinamide ribose and the phenolic oxygen of
catalytic Tyr198. In this mode of binding of the substrate, the
pantetheine moiety, covalently attached to the C1 atom of the
enoyl moiety of the substrate, would fit into the tunnel formed
by the protein residues 139–140, 202, and 240–244 and the
atoms of the nicotinamide ribose. Although the conformation of
the pantetheine arm of the substrate cannot be unambiguously
defined in this model, the general similarity of the substrate to
diazaborine strongly suggests that, in the enzyme-substrate
complex, the 236–246 loop might adopt a closely related helical
conformation, stabilizing the substrate bound to ENR through
van der Waals contacts.
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